secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000010795-24-000078
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD Q4 FY2024 revenue $5.4B (+6.9%), adjusted EPS $3.81 (+11.4%); issues FY25 EPS guidance $14.25-$14.60
--------------------------------------------------------------------------------

- Q4 revenue $5.4B, +6.9% as reported; GAAP EPS $1.45 (vs $0.53), adjusted EPS $3.81 (vs $3.42).
- FY24 revenue $20.2B, +4.2%; adjusted EPS $13.14 (+7.6%); free cash flow $3.1B (+47.4%).
- FY25 guidance: organic revenue growth 4.0-4.5%; adjusted diluted EPS $14.25-$14.60 (midpoint ~10% growth).
- Completed acquisition of Edwards Lifesciences' Critical Care product group, expanding smart connected care portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000078/0000010795-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000078/bdx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000010795-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer